Sato Y, Ishikawa K, Iwata S, Akita H, Oikawa T, Sunakawa K
Department of Pediatrics, Ota General Hospital.
Jpn J Antibiot. 1989 Mar;42(3):579-93.
Pharmacokinetic and bacteriological studies were carried out on sulbactam/ampicillin (SBT/ABPC) in the field of pediatrics. The results obtained are summarized as follows: 1. A total of 248 clinical isolates were employed to determine minimum inhibitory concentrations (MIC) of SBT/ABPC against various bacterial species. SBT/ABPC showed stronger antibacterial activity against Gram-positive organisms than against Gram-negative rods. 2. The peak serum level of ABPC was about twice as high as that of SBT, and serum levels of ABPC and SBT declined with time. Both drugs showed almost the same trend of changes in concentrations. The half-lives of both drugs were about 1 hour. 3. The urinary recovery rates over 6 hours after administration were 52-80% for ABPC and 70-73% for SBT. 4. The effect of SBT/ABPC on coagulation system was examined. No case showed changes in PT, APTT, TT and HPT before and after administration of SBT/ABPC. Platelet aggregation during administration of SBT/ABPC was slightly faster than that before administration, suggesting that SBT/ABPC had no effect on platelet aggregation. Generally speaking, it seemed that SBT/ABPC was a safe antibiotic for bleeding. 5. The effect of SBT/ABPC on the intestinal bacterial flora in experimental animals was examined. Escherichia coli, Enterococcus faecalis, Bacteroides fragilis and Bifidobacterium breve were reduced after administration of SBT/ABPC, suggesting that the intestinal bacterial flora was affected by the administration of SBT/ABPC more greatly than by the administration of ABPC alone. In a similar investigation being made with clinical cases, both aerobes and anaerobes showed great changes. Concentrations of the drugs in feces increased with increasing dosage, resulting in greater changes of the intestinal bacterial flora. Thus, the total number of aerobes and anaerobes was reduced. No diarrhea was observed in any subjects examined. From the above results, it appeared that SBT/ABPC was a safe and useful antibiotic for various bacterial infections in the field of pediatrics.
在儿科领域对舒巴坦/氨苄西林(SBT/ABPC)进行了药代动力学和细菌学研究。所得结果总结如下:1. 共使用248株临床分离菌株来测定SBT/ABPC对各种细菌的最低抑菌浓度(MIC)。SBT/ABPC对革兰氏阳性菌的抗菌活性强于革兰氏阴性杆菌。2. ABPC的血清峰值水平约为SBT的两倍,且ABPC和SBT的血清水平随时间下降。两种药物的浓度变化趋势几乎相同。两种药物的半衰期均约为1小时。3. 给药后6小时内ABPC的尿回收率为52 - 80%,SBT为70 - 73%。4. 检测了SBT/ABPC对凝血系统的影响。在给予SBT/ABPC前后,无一例PT、APTT、TT和HPT出现变化。SBT/ABPC给药期间的血小板聚集略快于给药前,表明SBT/ABPC对血小板聚集无影响。一般来说,SBT/ABPC似乎是一种对出血安全的抗生素。5. 检测了SBT/ABPC对实验动物肠道菌群的影响。给予SBT/ABPC后,大肠杆菌、粪肠球菌、脆弱拟杆菌和短双歧杆菌数量减少,表明SBT/ABPC给药对肠道菌群的影响比单独给予ABPC更大。在对临床病例进行的类似研究中,需氧菌和厌氧菌均出现了很大变化。粪便中药物浓度随剂量增加而升高,导致肠道菌群变化更大。因此,需氧菌和厌氧菌的总数减少。在所检查的任何受试者中均未观察到腹泻。从上述结果来看,SBT/ABPC似乎是儿科领域用于治疗各种细菌感染的一种安全且有效的抗生素。